The long range goal of this project is to develop methods of quantifying the dopamine transporter (DAT) site in human brain to provide insight into the neuroscience of addictive behavior in cocaine abuse. Positron emission tomography (PET) imaging studies will be employed to measure the DAT density and occupancy. The first goal will be to develop quantitative measurement of absolute density (B/max) in normal human brain as an improvement over existing measures of B/max/K/D. Two methods will be studied, one with unlabeled mazindol and IV unlabeled WIN 35,428 given prior to the second of two high specific activity [11/C] WIN 35,428 PET scans. Using quantitative model calculations, B/max will be obtained. Validation of these techniques in postmortem baboon brains will be performed. Upon successful development of this procedure, we will apply these methods to obtain B/max in cocaine users immediately after cocaine withdrawal and one month later. The change in B/max will be compared with test-retest of B/max in normal volunteers studied at the same interval. This will allow examination of the brain response variability to long-term cocaine abuse and comparison to control B/max values. A parallel study will also be employed to examine the pharmacokinetics of potential medications for cocaine abuse. The first step will be to test the hypothesis that time to peak drug level in brain is inversely correlated with the behavioral response. Not only will this be tested with plasma levels but specifically with the onset of peak occupancy levels against subjective effects of IV cocaine. Testing of such hypotheses is a fundamental element in the understanding of drug abuse and dopamine. This will be done by monitoring the effects of IV cocaine given at different time intervals on the reduction in binding of cocaine given by programmed infusion. This will allow the relationship of DAT occupancy vs. drug dose injection rate. The next step is to measure the DAT occupancy for varying levels of two putative medications, oral GBR 12909 and IV unlabelled WIN 35,428. By measuring the dose response of DAT occupancy vs. drug dose, a number of steps towards medication development are achieved. These include determination of the drub doses at which percent occupancy is high and most optimal; examination of the subjective effects of these drugs when given orally or by slow infusion, thereby determining their suitability as therapeutic drugs. At the conclusion of this five year project, important neuroscience information concerning measurement of DAT in cocaine withdrawal will be obtained. A fundamental hypothesis of drug abuse and drug delivery will be tested. Furthermore, the DAT occupancy vs. dose relationships will be developed and applied to two putative treatment drugs, as a first step towards rational drug trials. The possible non-competitive nature of GBR 12909 will also be tested in vivo.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA009482-05
Application #
2872072
Study Section
Special Emphasis Panel (SRCD)
Project Start
1994-09-30
Project End
2002-01-31
Budget Start
1999-03-15
Budget End
2002-01-31
Support Year
5
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Braši?, James Robert; Bibat, Genila; Kumar, Anil et al. (2012) Correlation of the vesicular acetylcholine transporter densities in the striata to the clinical abilities of women with Rett syndrome. Synapse 66:471-82
Brasic, James Robert; Cascella, Nicola; Kumar, Anil et al. (2012) Positron emission tomography experience with 2-[ýýýýýF]fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-[ýýýýýF]FA) in the living human brain of smokers with paranoid schizophrenia. Synapse 66:352-68
Alexander, Mohab; Rothman, Richard B; Baumann, Michael H et al. (2005) Noradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboon Papio anubis. Synapse 56:94-9
Kerenyi, Levente; Ricaurte, George A; Schretlen, David J et al. (2003) Positron emission tomography of striatal serotonin transporters in Parkinson disease. Arch Neurol 60:1223-9
Zhou, Yun; Endres, Christopher J; Brasic, James Robert et al. (2003) Linear regression with spatial constraint to generate parametric images of ligand-receptor dynamic PET studies with a simplified reference tissue model. Neuroimage 18:975-89
Yokoi, Fuji; Grunder, Gerhard; Biziere, Kathleen et al. (2002) Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 27:248-59
Singer, Harvey S; Szymanski, Sally; Giuliano, Joseph et al. (2002) Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET. Am J Psychiatry 159:1329-36
Gjedde, A; Wong, D F (2001) Quantification of neuroreceptors in living human brain. v. endogenous neurotransmitter inhibition of haloperidol binding in psychosis. J Cereb Blood Flow Metab 21:982-94
Cumming, P; Yokoi, F; Chen, A et al. (1999) Pharmacokinetics of radiotracers in human plasma during positron emission tomography. Synapse 34:124-34
Villemagne, V L; Wong, D F; Yokoi, F et al. (1999) GBR12909 attenuates amphetamine-induced striatal dopamine release as measured by [(11)C]raclopride continuous infusion PET scans. Synapse 33:268-73

Showing the most recent 10 out of 15 publications